Aerpio Pharmaceuticals Inc. (ARPO)’s Financial Results Comparing With Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)

We will be contrasting the differences between Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerpio Pharmaceuticals Inc. 1 1.67 N/A -0.36 0.00
Paratek Pharmaceuticals Inc. 5 5.88 N/A -3.76 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Aerpio Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc.


Table 2 shows us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
Aerpio Pharmaceuticals Inc. 0.00% -20.5% -17.7%
Paratek Pharmaceuticals Inc. 0.00% -232.6% -39.5%


The Current Ratio and a Quick Ratio of Aerpio Pharmaceuticals Inc. are 13.8 and 13.8. Competitively, Paratek Pharmaceuticals Inc. has 14.1 and 14 for Current and Quick Ratio. Paratek Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Aerpio Pharmaceuticals Inc.

Analyst Ratings

The table given features the ratings and recommendations for Aerpio Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aerpio Pharmaceuticals Inc. 0 0 0 0.00
Paratek Pharmaceuticals Inc. 0 0 2 3.00

On the other hand, Paratek Pharmaceuticals Inc.’s potential upside is 461.50% and its average price target is $21.

Insider and Institutional Ownership

Aerpio Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc. has shares owned by institutional investors as follows: 23.4% and 79%. Aerpio Pharmaceuticals Inc.’s share owned by insiders are 1.1%. On the other hand, insiders owned about 4.3% of Paratek Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aerpio Pharmaceuticals Inc. 0.13% -8.73% -22.06% -79.51% -80.37% -53.24%
Paratek Pharmaceuticals Inc. -3.87% -21.22% -40.41% -51.28% -67.54% -37.04%

For the past year Aerpio Pharmaceuticals Inc. was more bearish than Paratek Pharmaceuticals Inc.


Paratek Pharmaceuticals Inc. beats Aerpio Pharmaceuticals Inc. on 5 of the 8 factors.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.